ANAHEIM, CA (UroToday.com) - (ABST#1147 Prostate Cancer Basic Research V) - Andrea Gallina, MD and collaborators from numerous international institutions presented. “FAVORABLE LONG-TERM OUTCOMES IN PATIENTS WITH SEMINAL VESICLE INVASION OR LYMPH NODE INVASION AT RADICAL PROSTATECTOMY”. They hypothesized that a significant proportion of patients with either seminal vesicle invasion (SVI) or lymph node invasion (LNI) at radical prostatectomy (RP) may achieve good cancer control without adjuvant therapy. The rate of biochemical recurrence (BCR) was examined at 1, 3 and 5 years after RP.

Clinical and pathological data were available for 689 and 325 patients with SVI and LNI from 1 European and 2 North American referral centers, diagnosed with CaP between 1987 and 2006. All patients were subjected to retropubic RP and pelvic lymphadenectomy. Biochemical recurrence was defined as a PSA >0.1 ng/mL and rising. N0 patients received any adjuvant therapy before BCR. Kaplan-Meier curves assessed BCR-free survival.

In the SVI positive cohort, mean PSA was 11.9, pathologic Gleason score was 2-7 and 8-10 in 572 (83.0%) and 117 (17.0%) of patients, respectively. The actuarial BCR-free survival rate at 1, 3 and 5 years was 82, 60 and 46% for SVI patients with Gleason 2-7 vs. 55%, 31% and 22 for SVI patients with Gleason 8-10. In LNI positive cohort, mean PSA was 13.8. Pathologic Gleason sum was 2-7 and 8-10 in 220 and 105 patients, respectively. The actuarial BCR-free survival rate at 1, 3 and 5 years was 54, 40 and 29% for LNI patients with pathologic Gleason 2-7 vs. 30, 15 and 15% for Gleason 8-10 (p<0.001).

They conclude that the majority (83%) of SVI patients may enjoy a 46% BCR-free survival at 5 years from RP. Similarly, the majority of LNI patients (67.7%) may experience a 29% BCR-free survival at 5 years from RP.

UroToday.com Full Conference Reports

Written by Christopher P. Evans, MD, a Contributing Editor with UroToday.

Please log-in or register in order to submit comments.

Powered by AkoComment!